Majority of U.S. Patients Discontinue GLP-1 Weight Loss Drugs After Two Years

A recent analysis found that only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss remained on the medications after two years. This declining trend has initiated debates on the cost-effectiveness of such drugs, which can be expensive and may need long-term usage for significant results.


Devdiscourse News Desk | Updated: 10-07-2024 16:48 IST | Created: 10-07-2024 16:48 IST
Majority of U.S. Patients Discontinue GLP-1 Weight Loss Drugs After Two Years
AI Generated Representative Image

A recent analysis has revealed that only one in four U.S. patients who were prescribed Novo Nordisk's Wegovy or Ozempic for weight loss continued using the medications after two years. The analysis, which reviewed U.S. pharmacy claims, showed a steady decline in usage over time and provides a broader perspective on patients' real-world experiences than previous studies that covered shorter durations.

The evidence of many patients discontinuing these weight-loss therapies soon after starting has fueled debates about their cost-effectiveness for patients, employers, and government health plans. Wegovy and other GLP-1 receptor agonists can exceed $1,000 per month and often require prolonged usage to produce meaningful benefits.

Criticism over the high costs has come from figures including President Joe Biden, who highlighted concerns about the financial burden these drugs could impose on the healthcare system. An analysis of claims data by Prime Therapeutics and Magellan Rx Management, focusing on 3,364 individuals, found that only 15% were still using their GLP-1 medications after two years.

(Disclaimer: With inputs from agencies.)

Give Feedback